CP
SLNO

CenterBook Partners’s Soleno Therapeutics SLNO Stock Holding History

CenterBook Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-62,794
Closed -$4.24M – 675
2025
Q3 		$4.24M Buy
62,794
+38,282
+156% +$2.84M 0.21% 131
2025
Q2 		$2.05M Buy
24,512
+8,158
+50% +$611K 0.11% 220
2025
Q1 		$1.17M Sell
16,354
-13,782
-46% -$671K 0.07% 293
2024
Q4 		$1.35M Buy
+30,136
New +$1.56M 0.08% 284

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CenterBook Partners's SLNO Position: Q4 2025 in Review

CenterBook Partners sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 62,794 shares — an estimated $4.24M sold.

CenterBook Partners first reported a position in SLNO in Q4 2024 and held it in 4 quarters. The position peaked at $4.24M in Q3 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • CenterBook Partners reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • CenterBook Partners sold 62,794 Soleno Therapeutics shares in Q4 2025, an estimated $4.24M.
  • CenterBook Partners first reported a position in Soleno Therapeutics in Q4 2024 and held it in 4 quarters.
  • CenterBook Partners's Soleno Therapeutics position peaked at $4.24M in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on CenterBook Partners's 13F filing for Q4 2025, filed 11 Feb 2026.